by Press Release on (#3GJ0A)
The Food and Drug Administration (FDA) is advising caution before prescribing the antibiotic clarithromycin (Biaxin) to patients with heart disease because of a potential increased risk of heart problems or death that can occur years later. FDAs recommendation is based on a review of the results of a 10-year follow-up study of patients with coronary heart […]The post FDA issues warning concerning prescribing Biaxin to patients with heart disease appeared first on Outbreak News Today.